Chromatin accessibility in leukemia: mapping and the limits of reprogramming
In a recent study published in Nature, Ochi et al. used ATAC-seq to profile bone marrow or peripheral blood tumor cells from 1563 newly diagnosed cases of acute myeloid leukemia (AML), resolving the disease into 16 chromatin-accessibility subgroups (the eCHROMA study) with independent prognostic and pharmacological value, most of them invisible to current genetic classification. 1 This chromatin-based framework raises a sharper question: how much of that architecture can actually be engineered by drugs designed to rewrite it?
Authors
- João Agostinho Machado‐Neto (ORCID: https://orcid.org/0000-0002-2937-8109)
- Diego A. Pereira‐Martins (ORCID: https://orcid.org/0000-0002-3302-4311)
- Juan Luiz Coelho‐Silva (ORCID: https://orcid.org/0000-0001-8384-6551)
Institutions
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- Universidade de São Paulo (BR)
Publication Details
- Journal
- Signal Transduction and Targeted Therapy
- Published
- 2026-10-04
- DOI
- https://doi.org/10.1038/s41392-026-03020-9
- Primary Topic
- Chromatin Remodeling and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Conselho Nacional de Desenvolvimento Científico e Tecnológico